Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Exocrine Pancreatic Insufficiency
Interventions
DEVICE

RELiZORB

Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.

DEVICE

Placebo

Sham device

Trial Locations (11)

15224

Children's Hospital of Pittsburgh, Pittsburgh

37332

Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville

43205

Nationwide Children's Hospital, Columbus

44106

Rainbow Babies and Children's Hospital, Cleveland

46202

Riley Hospital for Children at Indiana University Health, Indianapolis

53226

Children's Hospital of Wisconsin, Milwaukee

63104

Cardinal Glennon Children's Medical Center, St Louis

64108

Children's Mercy Hospital, Kansas City

83712

St. Luke's Cystic Fibrosis Center of Idaho, Boise

90027

Children's Hospital of Los Angeles, Los Angeles

04102

Maine Medical Center, Portland

Sponsors
All Listed Sponsors
lead

Alcresta Therapeutics, Inc.

INDUSTRY